Paula Ragan is President and CEO of X4 Pharmaceuticals, Inc. Currently has a direct ownership of 765,068 shares of XFOR, which is worth approximately $504,944. The most recent transaction as insider was on Mar 11, 2024, when has been sold 49,678 shares (Common Stock) at a price of $0.88 per share, resulting in proceeds of $43,716. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 765K
0% 3M change
40.69% 12M change
Total Value Held $504,944

Paula Ragan Transaction History

Date Transaction Value Shares Traded Shares Held Form
Mar 11 2024
SELL
Open market or private sale
$43,716 $0.88 p/Share
49,678 Reduced 6.1%
765,068 Common Stock
Feb 12 2024
SELL
Open market or private sale
$21,911 $1.01 p/Share
21,695 Reduced 2.59%
814,746 Common Stock
Nov 03 2023
SELL
Open market or private sale
$35,915 $0.9 p/Share
39,906 Reduced 4.55%
836,441 Common Stock
Nov 01 2023
SELL
Open market or private sale
$145,657 $0.73 p/Share
199,531 Reduced 18.55%
876,347 Common Stock
Oct 31 2023
BUY
Grant, award, or other acquisition
-
532,081 Added 33.09%
1,075,878 Common Stock
Jun 23 2023
SELL
Open market or private sale
$12,910 $1.92 p/Share
6,724 Reduced 1.22%
543,797 Common Stock
Jun 15 2023
SELL
Open market or private sale
$14,994 $2.23 p/Share
6,724 Reduced 1.21%
550,521 Common Stock
May 31 2023
SELL
Open market or private sale
$12,269 $1.95 p/Share
6,292 Reduced 1.12%
557,245 Common Stock
Mar 10 2023
SELL
Open market or private sale
$41,729 $0.84 p/Share
49,678 Reduced 8.1%
563,537 Common Stock
Feb 13 2023
SELL
Open market or private sale
$20,176 $0.93 p/Share
21,695 Reduced 3.42%
613,215 Common Stock
Aug 17 2022
SELL
Open market or private sale
-
13,448 Reduced 2.07%
634,910 Common Stock
Jun 24 2022
SELL
Open market or private sale
-
6,724 Reduced 1.03%
648,358 Common Stock
Jun 16 2022
SELL
Open market or private sale
-
6,724 Reduced 1.02%
655,082 Common Stock
Jun 03 2022
SELL
Open market or private sale
$7,613 $1.21 p/Share
6,292 Reduced 0.94%
661,806 Common Stock
Mar 01 2022
BUY
Grant, award, or other acquisition
-
220,789 Added 24.84%
668,098 Common Stock
Feb 11 2022
SELL
Open market or private sale
-
21,695 Reduced 4.63%
447,309 Common Stock
Aug 17 2021
SELL
Open market or private sale
$68,585 $5.1 p/Share
13,448 Reduced 2.79%
469,004 Common Stock
Jul 15 2021
SELL
Open market or private sale
$77,729 $5.78 p/Share
13,448 Reduced 2.71%
482,452 Common Stock
Jun 23 2021
BUY
Grant, award, or other acquisition
-
44,826 Added 8.29%
495,900 Common Stock
Jun 15 2021
BUY
Grant, award, or other acquisition
-
44,826 Added 9.04%
451,074 Common Stock
Jun 02 2021
SELL
Open market or private sale
$22,800 $9.5 p/Share
2,400 Reduced 0.59%
406,248 Common Stock
Jun 01 2021
SELL
Open market or private sale
$38,619 $9.41 p/Share
4,104 Reduced 0.99%
408,648 Common Stock
May 03 2021
SELL
Open market or private sale
$19,992 $8.33 p/Share
2,400 Reduced 0.58%
412,752 Common Stock
Apr 05 2021
SELL
Open market or private sale
$22,008 $9.17 p/Share
2,400 Reduced 0.57%
415,152 Common Stock
Mar 24 2021
BUY
Grant, award, or other acquisition
-
144,629 Added 25.73%
417,552 Common Stock
PR

Paula Ragan

President and CEO
Boston, MA

Track Institutional and Insider Activities on XFOR

Follow X4 Pharmaceuticals, Inc and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XFOR shares.

Notify only if

Insider Trading

Get notified when an X4 Pharmaceuticals, Inc insider buys or sells XFOR shares.

Notify only if

News

Receive news related to X4 Pharmaceuticals, Inc

Track Activities on XFOR